Suven Life Sciences secures Product Patents in Australia and Singapore

The granted claims of the patents include the class of selective H3 Inverse agonists and 5HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Narcolepsy, Parkinson and Schizophrenia respectively. Read The Rest at :